Health and Healthcare
Oppenheimer Has 5 Sizzling Biotech Stocks to Buy Now Trading Under $10
Published:
Last Updated:
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy. Many of the biggest public companies, especially the technology giants, trade in the hundreds, all the way up to over $1,000 per share or more. At those steep prices, it is difficult to get any decent share count leverage.
Many investors, especially more aggressive traders, look at lower-priced stocks as a way to not only make some good money but to get a higher share count. That can really help the decision-making process, especially when you are on to a winner, as you can always sell half and keep half.
Oppenheimer is one of the top investment banks on Wall Street, so we screened the firm’s outstanding research database and found five biotech stocks trading for less than $10 per share that could provide investors with some solid upside potential.
While all five are rated Overweight at the firm, they are much better suited for aggressive investors. It is important to remember that no single analyst report should be used as a sole basis for any buying or selling decision.
This micro-cap stock has some big upside to the Oppenheimer price target. CASI Pharmaceuticals Inc. (NASDAQ: CASI) is a biopharmaceutical company that develops and commercializes therapeutics and pharmaceutical products in China, the United States and elsewhere.
The company offers Evomela, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma, which has completed Phase 1 studies in China.
It also provides the following:
The Oppenheimer price target for the shares is a whopping $5, while the consensus target is $4.20. The stock recently rose above $1.50 per share.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.